Abstracts tagged "osteoarthritis and rheumatoid arthritis (RA)"

Abstract Number: 1453 • 2014 ACR/ARHP Annual Meeting
Gastrointestinal Risk Factors and Treatment Patterns of Rheumatoid Arthritis Versus Osteoarthritis Patients in Korea
Eun Young Lee¹, Sang Heon Lee², Hyo-Jin Kim³ and Korea RA/OA OR Group, ¹Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Dept of Internal Medicine, Konkuk University Hospital, Seoul, South Korea, ³Pfizer Tower, 1-11, Hoehyun-Dong 3-Ga, Jung-Gu, Seoul, South Korea
Background/Purpose Little is known about local data of the gastrointestinal risk faocts (GI) and treatment pattenrs in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. This study aimed to investigate and compare…
Abstract Number: 402 • 2014 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?
Masao Sato^1,2, Masao Takemura^2,3, Kuniaki Saito⁴ and Yasuko Yamamoto⁴, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan, ³Informative Laboratory Merdicine, Gifu University, Gifu, Japan, ⁴Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…
Abstract Number: 1326 • 2013 ACR/ARHP Annual Meeting
Discriminative Metabolite Profiling Of Synovial Fluid In Rheumatoid Arthritis Compared To Osteoarthritis
Jiwon Hwang¹, Joong Kyong Ahn², Jaejoon Lee¹, Inyoung Kim¹, Seulkee Lee¹, Chan Hong Jeon³, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea
Background/Purpose: Metabolomics is the study of unique chemical imprints that represent specific cellular processes in a cell, tissue, organ or organism. Synovial fluid in pathologic…
Abstract Number: 372 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. This association is thought to be due to the chronic inflammatory disease…
Abstract Number: 2673 • 2013 ACR/ARHP Annual Meeting
Mortality In Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With The General Population
Aleksandra Turkiewicz¹, Tuhina Neogi², George Peat³ and Martin Englund⁴, ¹Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Research Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: There is strong evidence in support of increased mortality in patients with rheumatoid arthritis (RA), while the relation is more controversial in osteoarthritis (OA).…
Abstract Number: 2434 • 2012 ACR/ARHP Annual Meeting
Effects of Interventions That Aim to Increase Exercise Adherence in People with Arthritis: A Best Evidence Synthesis
Katie, E. MacPherson¹, Allison M. Ezzat², Jenny Leese³ and Linda C. Li⁴, ¹New Westminster, BC, Canada, ²School of Rehabilitation Science, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre, Vancouver, BC, Canada, ⁴Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Exercise is a central component in treatment and rehabilitation for chronic musculoskeletal conditions. Current literature supports the use of therapeutic exercise to reduce pain,…
Abstract Number: 2124 • 2012 ACR/ARHP Annual Meeting
Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: Interferon (IFN) exerts antiviral and antineoplastic activities, and is involved in immunoregulatory activities. IFN probably plays an important role in the pathogenesis of rheumatoid…
Abstract Number: 430 • 2012 ACR/ARHP Annual Meeting
Comprehensive Microrna Analysis Identifies Mir-24, Mir-26a, and Mir-125a-5p As Plasma Biomarkers for Rheumatoid Arthritis
Koichi Murata¹, Moritoshi Furu², Hiroyuki Yoshitomi³, Masahiro Ishikawa¹, Hideyuki Shibuya¹, Hiromu Ito² and Shuichi Matsuda¹, ¹Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: MicroRNAs (miRNAs) are present in human plasma in a stable form despite the endogenous RNase activity. Plasma miRNAs are non-invasive biomarker for cancer detection…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].